Source comparison
MOTS-c for Biological Age Reduction: Comparison Table
Before committing to any longevity peptide protocol, understanding how MOTS-c compares to other validated interventions helps clarify realistic expectations. MOTS-c AMPK activation, mitochondrial biogenesis, insulin sensitivity Moderate (Phase II RCTs publishe
This comparison does not assign a generated winner or score.
- Before committing to any longevity peptide protocol, understanding how MOTS-c compares to other validated interventions helps clarify realistic expectations.
- MOTS-c
- AMPK activation, mitochondrial biogenesis, insulin sensitivity
- Moderate (Phase II RCTs published)
- 5–10mg subcutaneous, 2–3×/week
- Improved glucose tolerance, reduced insulin resistance, modest fat loss
- Strong metabolic benefits in insulin-resistant populations; less clear benefit in metabolically healthy individuals
- Metformin
- AMPK activation, Complex I inhibition, reduced hepatic glucose output
- Strong (decades of human use, TAME trial ongoing)
- 500–2000mg daily oral
- Improved insulin sensitivity, reduced fasting glucose, possible lifespan extension
- Gold standard for metabolic longevity interventions; proven track record but modest effect size
- NAD+ Precursors (NMN, NR)
- NAD+ repletion, sirtuin activation
- Moderate (multiple Phase II trials)
- 250–1000mg daily oral
- Improved mitochondrial function, possible cardiovascular benefit
- Variable absorption; benefits strongest in NAD-depleted populations
- Rapamycin (mTOR inhibitor)
- mTOR pathway suppression, autophagy induction
- Strong (animal models), weak (human longevity data)
- 5–10mg weekly oral (off-label)
- Autophagy induction, immune suppression, possible lifespan extension
- Most robust animal data for lifespan extension; significant immunosuppressive effects limit use